Cowen & Co. Annual Healthcare Conference March 9-13:
National Comprehensive Cancer Network Annual Meeting (NCCN) March 10:
Human Genome Sciences ( HGSI): FDA drug approval decision date for Benlysta in lupus.
Dendreon ( DNDN): FDA approval decision for expansion of Provenge manufacturing capacity at New Jersey facility. March 18-22:
American Academy of Allergy, Asthma & Immunology (AAAAI) annual meeting. March 24-27:
American Academy of Pain Medicine (AAPM) meeting. March 26:
Bristol-Myers Squibb ( BMY): FDA drug approval decision date for Yervoy in melanoma. March 30 - April 3:
European Association for the Study of the Liver (EASL) annual meeting. Other potential biotech events in March: Cell Therapeutics ( CTIC): Outcome of FDA appeal meeting for pixantrone in aggressive non-Hodgkin's lymphoma A.P. Pharma ( APPA): Meeting with FDA to discuss requirements for resubmission of APF530 for chemotherapy-induced nausea following last year's rejection letter. Achillion Pharmaceuticals: ( ACHN) Top-line results from 28-day, phase IIa study of hepatitis C drug ACH-1625. Celgene ( CELG): Top-line results from phase II study of amrubicin in small-cell lung cancer. Corcept Therapeutics: ( CORT) FDA approval filing for Corlux in Cushing's syndrome. --Written by Adam Feuerstein in Boston. >To contact the writer of this article, click here: Adam Feuerstein. >To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein. >To submit a news tip, send an email to: firstname.lastname@example.org.